Form 4: Pulmonx CEO Steven S. Williamson Reports Stock Transactions and Option Grant

Pulmonx CEO Steven S. Williamson reports the sale of shares to cover tax obligations, acquisition of shares through the employee stock purchase plan, grant of restricted stock units, and grant of employee stock options.

Summary

• On March 3, 2025, Steven S. Williamson, CEO of Pulmonx Corp, reported transactions involving the company's stock.
• He sold 27,689 shares at $7.14 to cover tax obligations related to vesting Restricted Stock Units (RSUs).
• Williamson acquired 181,696 shares through the grant of RSUs, which vest in equal quarterly installments over four years from March 3, 2025.
• He also acquired 2,500 shares under the Issuer's 2020 Employee Stock Purchase Plan on February 21, 2025.
• Additionally, Williamson was granted an employee stock option to purchase 128,395 shares at an exercise price of $8.29, vesting in 48 equal monthly installments from March 3, 2025.
• Following these transactions, Williamson beneficially owns 376,038 shares of common stock and holds options for 128,395 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reports routine transactions related to executive compensation. While the sale of shares could be perceived negatively, it is explained as covering tax obligations. The grants of RSUs and stock options are generally positive signals.

Positives

• The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders.
• Participation in the Employee Stock Purchase Plan demonstrates confidence in the company's future.

Negatives

• The sale of shares to cover tax obligations, while common, could be perceived negatively by some investors.

Risks

• Executive stock sales can sometimes be interpreted as a lack of confidence in the company's future prospects, although this sale was explicitly for tax obligations.
• The vesting schedule of the RSUs and stock options could incentivize short-term decision-making.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives and their holdings of company stock.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in publicly traded companies, particularly in the technology and healthcare sectors.
• Vesting schedules, such as the four-year vesting period for the RSUs and monthly vesting for the stock options, are also typical.
• Companies like Medtronic, Boston Scientific, and Stryker also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders' perception of the company, depending on how they interpret the stock sale.
• Employees may be affected by the vesting of RSUs and stock options, which can influence their motivation and retention.

Key Dates